Sleep Problems — Understanding Sleep Problems in Children With Autism Spectrum Disorder
Citation(s)
Allik H, Larsson JO, Smedje H Insomnia in school-age children with Asperger syndrome or high-functioning autism. BMC Psychiatry. 2006 Apr 28;6:18.
Aman MG, Singh NN, Stewart AW, Field CJ The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985 Mar;89(5):485-91.
Bradley EA, Summers JA, Wood HL, Bryson SE Comparing rates of psychiatric and behavior disorders in adolescents and young adults with severe intellectual disability with and without autism. J Autism Dev Disord. 2004 Apr;34(2):151-61.
Garstang J, Wallis M Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev. 2006 Sep;32(5):585-9.
Giannotti F, Cortesi F, Cerquiglini A, Bernabei P An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord. 2006 Aug;36(6):741-52.
Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y Brief report: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord. 1995 Dec;25(6):641-54.
O'Brien LM, Gozal D Neurocognitive dysfunction and sleep in children: from human to rodent. Pediatr Clin North Am. 2004 Feb;51(1):187-202. Review.
Owens JA, Spirito A, McGuinn M The Children's Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. Sleep. 2000 Dec 15;23(8):1043-51.
Patzold LM, Richdale AL, Tonge BJ An investigation into sleep characteristics of children with autism and Asperger's Disorder. J Paediatr Child Health. 1998 Dec;34(6):528-33.
Polimeni MA, Richdale AL, Francis AJ A survey of sleep problems in autism, Asperger's disorder and typically developing children. J Intellect Disabil Res. 2005 Apr;49(Pt 4):260-8.
Quine L Sleep problems in children with mental handicap. J Ment Defic Res. 1991 Aug;35 ( Pt 4):269-90.
Richdale AL, Prior MR The sleep/wake rhythm in children with autism. Eur Child Adolesc Psychiatry. 1995 Jul;4(3):175-86.
Robinson AM, Richdale AL Sleep problems in children with an intellectual disability: parental perceptions of sleep problems, and views of treatment effectiveness. Child Care Health Dev. 2004 Mar;30(2):139-50.
Voultsios A, Kennaway DJ, Dawson D Salivary melatonin as a circadian phase marker: validation and comparison to plasma melatonin. J Biol Rhythms. 1997 Oct;12(5):457-66.
Weiss MD, Wasdell MB, Bomben MM, Rea KJ, Freeman RD Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J Am Acad Child Adolesc Psychiatry. 2006 May;45(5):512-9.
Wiggs L, Stores G Severe sleep disturbance and daytime challenging behaviour in children with severe learning disabilities. J Intellect Disabil Res. 1996 Dec;40 ( Pt 6):518-28.
Wiggs L, Stores G Sleep patterns and sleep disorders in children with autistic spectrum disorders: insights using parent report and actigraphy. Dev Med Child Neurol. 2004 Jun;46(6):372-80.
Characterization of Endogenous Melatonin Profiles in Children With Autism Spectrum Disorder.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.